Single Technology Appraisals (STAs)

2017

Baricitinib for treating moderate to severe rheumatoid arthritis [ID979].

2016

Ponatinib for treating chronic myeloid leukaemia [ID671].

Ibrutinib for treating Waldenstrom’s macroglobulinaemia [ID884].

Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753].

Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma [ID841].

Pertuzumab for treating early, HER 2 positive breast cancer [ID767].

Certolizumab pegol for treating rheumatoid arthritis following inadequate response to a TNF inhibitor [ID824].

Idiopathic pulmonary fibrosis - pirfenidone [ID837].

Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812].

Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer [ID889].

Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy [ID735].

Hypercholesterolaemia (primary), dyslipidaemia (mixed) - evolocumab [ID765].

Vedolizumab for treating moderate to severe active Crohn’s disease after prior therapy [ID690].

Vedolizumab for ulcerative colitis [ID691].

Degarelix for the treatment of advanced hormone-dependent prostate cancer [ID590].

Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C [ID742].

Sipuleucel-T for the treatment of metastatic castrate-resistant prostate cancer [ID573].

2015

Mepolizumab for treating severe eosinophilic asthma [ID798].

2014

Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2 - positive breast cancer after treatment with trastuzumab and a taxane [ID603] Report.

Nalmefene for reduction of alcohol consumption in alcohol-dependent patients [ID660] Report.

Lorcaserin for obesity [ID337].

Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome [ID532Report

2013

Rituximab in combination with corticosteroids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID567Report

Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents [ID305Report

2012

Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional urate-lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated [ID521] Report

Alteplase for treating acute ischaemic stroke (review of technology appraisal guidance 122) [ID536Report

Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism [ID437Report

Bivalirudin for the treatment of ST-segment elevation myocardial infarction (10/09/01Report.

Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (10/24/01Report.

Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs (08/118/01Report.

Mifamurtide for the treatment of osteosarcoma (08/77/01Report.

2011

Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer (10/49/01) Report

2010

Trabectedin for the treatment of relapsed ovarian cancer (08/212/01) Report

Bevacizumab in combination with oxaliplatin and either 5FU or capecitabine for the treatment of metastatic colorectal cancer (08/211/01).

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma (08/92/01).

2009

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (08/03/01).

Febuxostat for the management of hyperuricaemia in people with gout (07/69/01).

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (07/90/01).

Varenicline for smoking cessation (06/50/01).

Alteplase for the treatment of acute ischaemic stroke (06/51/01).

Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal (05/53/01).

Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal (05/51/01).